Kopran

{
  "main_header": {
    "sid": 568367,
    "name": "Kopran",
    "stock_name": "Kopran",
    "full_name": "Kopran Ltd",
    "name_url": "stocks-analysis/kopran",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "142.80",
    "chg": 0.95,
    "chgp": "0.67%",
    "dir": 1,
    "prev_price": "141.85",
    "mcapval": "700.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524280,
    "symbol": "KOPRAN",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE082A01010",
    "curr_date": "Feb 10",
    "curr_time": "",
    "bse_nse_vol": "1.56 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 10, 2026",
    "traded_date_str": "2026 02 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kopran-568367-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Kopran Ltd Gains 9.48%: 3 Key Factors Driving the Weekly Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-gains-948-3-key-factors-driving-the-weekly-rally-3826563",
        "imagepath": "",
        "date": "2026-02-07 17:00:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Feb:</strong> New 52-week low (Rs.123.2)</p>\n                    <p><strong>4 Feb:</strong> Investment rating upgraded to Sell from Strong Sell</p>\n                    <p><strong>5 Feb:</strong> Technical momentum shifts amid mixed signals, stock gains 3.46%</p>\n                    <p><strong>6 Feb:</strong> Week closes at Rs.140.30, up 9.48% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.128.15</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.140.30</div><div class=..."
      },
      {
        "title": "Kopran Ltd Upgraded to Sell: A Detailed Analysis of Quality, Valuation, Financial Trend, and Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kopran-ltd-upgraded-to-sell-a-detailed-analysis-of-quality-valuation-financial-trend-and-technicals-3821863",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/KopranLtd_mojoScore_3821863.png",
        "date": "2026-02-05 08:21:49",
        "description": "Kopran Ltd’s investment rating has been upgraded from Strong Sell to Sell as of 4 February 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 34.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation considerations."
      },
      {
        "title": "Kopran Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-technical-momentum-shifts-amid-mixed-market-signals-3821659",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/KopranLtd_technicaldot_3821659.png",
        "date": "2026-02-05 08:02:35",
        "description": "Kopran Ltd has exhibited a notable shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a nuanced change in investor sentiment. Despite a 3.46% gain in the latest session, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring the challenges faced by this Pharmaceuticals & Biotechnology player in the current market environment."
      },
      {
        "title": "Kopran Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kopran-ltd-is-rated-strong-sell-3816027",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/KopranLtd_mojoScore_3816027.png",
        "date": "2026-02-02 10:11:05",
        "description": "Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the most up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Kopran Ltd Stock Falls to 52-Week Low of Rs.123.2 Amid Continued Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-stock-falls-to-52-week-low-of-rs1232-amid-continued-underperformance-3815968",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/KopranLtd_priceRelatedfactors_3815968.png",
        "date": "2026-02-02 09:48:37",
        "description": "Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.123.2 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and market positioning."
      },
      {
        "title": "Kopran Ltd Falls 9.79%: 4 Key Factors Driving the Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-falls-979-4-key-factors-driving-the-weekly-decline-3803615",
        "imagepath": "",
        "date": "2026-01-24 17:00:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 19:</strong> Stock opens at ₹142.55, down 1.72% amid weak market sentiment</p>\n                    <p><strong>Jan 20:</strong> Downgrade to Strong Sell announced, stock falls 4.67% to ₹135.90</p>\n                    <p><strong>Jan 21:</strong> Bearish technical signals intensify, stock closes near ₹135.60</p>\n                    <p><strong>Jan 22:</strong> Mixed quarterly results released, slight uptick to ₹135.75</p>\n                    <p><strong>Jan 23:</strong> Financial trend improves marginally, but stock closes lower at ₹130.85</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open..."
      },
      {
        "title": "Are Kopran Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-kopran-ltd-latest-results-good-or-bad-3802450",
        "imagepath": "",
        "date": "2026-01-23 19:16:34",
        "description": "Kopran Ltd's latest financial results for Q3 FY26 present a complex picture of growth and challenges. The company reported a net profit of ₹9.34 crores, which reflects a decline of 10.19% year-on-year, despite a recovery from a loss in the previous quarter. Revenue for the same period was ₹194.28 crores, showcasing a significant quarter-on-quarter growth of 64.77% and a year-on-year increase of 16.87%. This revenue growth, however, is accompanied by concerns regarding profitability, as the operating margin (excluding other income) decreased to 9.15%, down from 11.93% a year prior, indicating rising operational costs that have outpaced revenue growth.\n\nThe profit after tax (PAT) margin also contracted to 4.81%, down from 6.26% in the corresponding quarter last year, highlighting ongoing challenges in maintaining bottom-line efficiency. Additionally, the company's return on equity (ROE) and return on capital ..."
      },
      {
        "title": "Kopran Ltd Reports Mixed Quarterly Results Amid Financial Trend Improvement",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-reports-mixed-quarterly-results-amid-financial-trend-improvement-3800923",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/KopranLtd_fintrenddot_3800923.png",
        "date": "2026-01-23 08:00:10",
        "description": "Kopran Ltd’s latest quarterly results for December 2025 reveal a modest improvement in its financial trend, shifting from very negative to negative territory. Despite achieving record net sales and improved cash reserves, the pharmaceutical company continues to grapple with declining profitability and rising interest costs, underscoring persistent operational challenges in a competitive sector."
      },
      {
        "title": "Kopran Ltd Q3 FY26: Margin Squeeze Amid Revenue Volatility Raises Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/kopran-ltd-q3-fy26-margin-squeeze-amid-revenue-volatility-raises-profitability-concerns-3800669",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/Kopran_quaterlyResult_3800669.png",
        "date": "2026-01-22 18:30:51",
        "description": "Kopran Limited, a Mumbai-based pharmaceutical manufacturer specialising in penicillin and non-penicillin-based drugs, reported net profit of ₹9.34 crores for Q3 FY26 (October-December 2025), marking a sharp reversal from the previous quarter's loss but representing a 10.19% year-on-year decline. The company's shares, trading at ₹135.75 on the National Stock Exchange, have witnessed a significant correction of 33.78% over the past year, substantially underperforming both the benchmark Sensex and the broader pharmaceuticals sector."
      }
    ],
    "total": 273,
    "sid": "568367",
    "stock_news_url": "https://www.marketsmojo.com/news/kopran-568367"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "23-Jan-2026",
      "details": "Newspaper Advertisement for the Q3 Results FY 2025-26",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "23-Jan-2026",
      "details": "Investor Presentation for Q3 FY 2025-26",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Results For Q3 FY 2025-26",
      "datetime": "22-Jan-2026",
      "details": "Unaudited Results for standalone and consolidated for Q3 FY 2025-26",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kopran Ltd has declared <strong>30%</strong> dividend, ex-date: 04 Sep 25",
          "dt": "2025-09-04",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Kopran Ltd Gains 9.48%: 3 Key Factors Driving the Weekly Rally

2026-02-07 17:00:06

Key Events This Week

2 Feb: New 52-week low (Rs.123.2)

4 Feb: Investment rating upgraded to Sell from Strong Sell

5 Feb: Technical momentum shifts amid mixed signals, stock gains 3.46%

6 Feb: Week closes at Rs.140.30, up 9.48% for the week

Week Open

Rs.128.15

Week Close

Rs.140.30

Read full news article

Kopran Ltd Upgraded to Sell: A Detailed Analysis of Quality, Valuation, Financial Trend, and Technicals

2026-02-05 08:21:49

Kopran Ltd’s investment rating has been upgraded from Strong Sell to Sell as of 4 February 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 34.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation considerations.

Read full news article

Kopran Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-05 08:02:35

Kopran Ltd has exhibited a notable shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a nuanced change in investor sentiment. Despite a 3.46% gain in the latest session, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring the challenges faced by this Pharmaceuticals & Biotechnology player in the current market environment.

Read full news article

Kopran Ltd is Rated Strong Sell

2026-02-02 10:11:05

Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Read full news article

Kopran Ltd Stock Falls to 52-Week Low of Rs.123.2 Amid Continued Underperformance

2026-02-02 09:48:37

Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.123.2 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and market positioning.

Read full news article

Kopran Ltd Falls 9.79%: 4 Key Factors Driving the Weekly Decline

2026-01-24 17:00:08

Key Events This Week

Jan 19: Stock opens at ₹142.55, down 1.72% amid weak market sentiment

Jan 20: Downgrade to Strong Sell announced, stock falls 4.67% to ₹135.90

Jan 21: Bearish technical signals intensify, stock closes near ₹135.60

Jan 22: Mixed quarterly results released, slight uptick to ₹135.75

Jan 23: Financial trend improves marginally, but stock closes lower at ₹130.85

Week Open...

Read full news article

Are Kopran Ltd latest results good or bad?

2026-01-23 19:16:34

Kopran Ltd's latest financial results for Q3 FY26 present a complex picture of growth and challenges. The company reported a net profit of ₹9.34 crores, which reflects a decline of 10.19% year-on-year, despite a recovery from a loss in the previous quarter. Revenue for the same period was ₹194.28 crores, showcasing a significant quarter-on-quarter growth of 64.77% and a year-on-year increase of 16.87%. This revenue growth, however, is accompanied by concerns regarding profitability, as the operating margin (excluding other income) decreased to 9.15%, down from 11.93% a year prior, indicating rising operational costs that have outpaced revenue growth. The profit after tax (PAT) margin also contracted to 4.81%, down from 6.26% in the corresponding quarter last year, highlighting ongoing challenges in maintaining bottom-line efficiency. Additionally, the company's return on equity (ROE) and return on capital ...

Read full news article

Kopran Ltd Reports Mixed Quarterly Results Amid Financial Trend Improvement

2026-01-23 08:00:10

Kopran Ltd’s latest quarterly results for December 2025 reveal a modest improvement in its financial trend, shifting from very negative to negative territory. Despite achieving record net sales and improved cash reserves, the pharmaceutical company continues to grapple with declining profitability and rising interest costs, underscoring persistent operational challenges in a competitive sector.

Read full news article

Kopran Ltd Q3 FY26: Margin Squeeze Amid Revenue Volatility Raises Profitability Concerns

2026-01-22 18:30:51

Kopran Limited, a Mumbai-based pharmaceutical manufacturer specialising in penicillin and non-penicillin-based drugs, reported net profit of ₹9.34 crores for Q3 FY26 (October-December 2025), marking a sharp reversal from the previous quarter's loss but representing a 10.19% year-on-year decline. The company's shares, trading at ₹135.75 on the National Stock Exchange, have witnessed a significant correction of 33.78% over the past year, substantially underperforming both the benchmark Sensex and the broader pharmaceuticals sector.

Read full news article

View All News